Latest Oncology News

ALRN-6924 Halts Development in P53-Mutant NSCLC, Advances in P53-Mutant Breast Cancer

July 1st 2022

Caroline Seymour

Drug manufacturer Aileron plans to stop further enrollment into a phase 1b trial (NCT04022876) after the chemoprotective agent ALRN-6924 missed its composite primary end point for patients with advanced p53-mutant non–small cell lung cancer.

KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC

July 1st 2022

Brittany Lovely

Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

July 1st 2022

Chris Ryan

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Grants Orphan Drug Designation to Evorpacept for AML

July 1st 2022

Caroline Seymour

The FDA has granted an orphan drug designation to evorpacept, a next-generation CD47 blocker, for use as a potential therapeutic option for patients with acute myeloid leukemia.

$FDA Approval Sought for Subcutaneous Epcoritamab for Relapsed/Refractory LBCL$

FDA Approval Sought for Subcutaneous Epcoritamab for Relapsed/Refractory LBCL

July 1st 2022

Kristi Rosa

Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022.

Latest Oncology Videos

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

Improving Outcomes in Patients With DLBCL

Dr. Park on the Role of Cemiplimab in Advanced Basal Cell Carcinoma

Mechanism of Action of Ruxolitinib

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

Dr. Yoon on Updated Data on Tislelizumab Plus Chemotherapy in ESCC

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

Dr. Luke on the Importance of a Multidisciplinary Approach in Basal Cell Carcinoma

Dr. Monk on the Need for Molecular Testing in Ovarian Cancer

Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care

A Focus on Frontline Treatment in Patients With DLBCL

Optimizing Frontline Therapy in ITP: Treatment Selection and Goals

Making a Diagnosis of Immune Thrombocytopenia

Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Dr. Lipson on the Current Treatment Landscape of Basal Cell Carcinoma

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

Managing Patients with Essential Thrombocythemia

Myeloproliferative Neoplasms: Essential Thrombocythemia

MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

Early-Stage HCC: Role of Adjuvant Therapy

Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies

Future Directions in the Management of HER2+ Breast Cancer

Patient Profile 1: Resection for Early/Intermediate Stage HCC

All Oncology News

Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

July 1st 2022

Tisch Cancer Institute

Study findings could be developed into less-invasive method.

More Novel Therapies Are on the Horizon in Multiple Myeloma

July 1st 2022

Darcy Lewis

Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma.

Disitamab Vedotin Shows Efficacy in HER2-Negative Metastatic Urothelial Carcinoma

June 30th 2022

Jason Harris

Disitamab vedotin demonstrated promising efficacy with a tolerable safety profile in patients with HER2-negative metastatic urothelial carcinoma.

Tremelimumab/Durvalumab Produces Favorable OS Benefit in Unresectable HCC Irrespective of ALBI Grade

June 30th 2022

Ryan Scott

A single priming dose of tremelimumab added to regular interval durvalumab generated significantly improved overall survival compared with sorafenib in the frontline setting for patients with unresectable hepatocellular carcinoma, irrespective of of their baseline albumin-bilirubin grade, according to updated data from the phase 3 HIMALAYA trial.

KRAS Mutations Represent Important Target in Expanding Treatment of Pancreatic Cancer

June 30th 2022

Chris Ryan

Philip A. Philip, MD, PhD, FRCP, discusses unmet needs for patients with pancreatic cancer, emerging targets and agents in the space, and his hopes for future developments in the field.

Tislelizumab Plus Chemotherapy Elicits Strong Survival Benefit in Esophageal Cancer

June 30th 2022

Ashling Wahner

The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma

Duma Discusses the Unique Challenges of Women With Lung Cancer

June 30th 2022

OncLive Staff

Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gender bias interferes with treatment.

Radiation Therapy as Effective as Surgery for Prostate Cancer

June 30th 2022

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey

Ronald D. Ennis, MD, shares how radiotherapy is an excellent treatment for many men with prostate cancer, providing a minimally-invasive treatment with low adverse effect risks.

Durvalumab Plus Chemotherapy Improves pCR in Resectable NSCLC

June 30th 2022

Caroline Seymour

Neoadjuvant treatment with durvalumab plus platinum-based chemotherapy led to a statistically significant improvement in pathologic complete response and major pathologic response compared with chemotherapy alone in patients with resectable non–small cell lung cancer, according to findings from a planned interim analysis of the phase 3 AEGEAN trial.

Metrics in Clinical Medicine and Clinical Trials Should Look Beyond the P Value

June 30th 2022

Maurie Markman, MD

From evaluating clinical outcomes to determining payment for services, measurements are important in health care.

Durvalumab Plus Chemotherapy Maintains OS Benefit in Advanced Biliary Tract Cancer

June 30th 2022

Caroline Seymour

The addition of durvalumab to gemcitabine and cisplatin demonstrated an improvement in overall survival vs gemcitabine and cisplatin plus placebo as frontline therapy in patients with advanced biliary tract cancer, regardless of primary tumor location.

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

Kristi Rosa

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Jason Harris

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

Kristi Rosa

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

Kristi Rosa

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

See All News